Milestone advances one of the largest new U.S. aluminum manufacturing investments in decades toward commercial shipments in 2027

BAY MINETTE, Ala., Oct. 7, 2026 /PRNewswire/ -- Novelis Inc., a leading sustainable aluminum solutions provider and the world leader in aluminum rolling and recycling, has produced the first coil on the cold mill at its $5 billion aluminum recycling and rolling plant in Bay Minette.

"Producing the first coil on the cold mill is an important step in commissioning Bay Minette and increasing the supply of rolled aluminum in the United States," said Steve Fisher, president and CEO of Novelis. "With the North American market being capacity constrained, this investment will help Novelis meet long-term market demand, strengthen our U.S. manufacturing footprint and increase the use of recycled content in our products."

Bay Minette is the first fully integrated aluminum recycling and rolling plant to be built in the United States in more than 40 years. When fully operational, the facility will add 600 kilotonnes of annual rolled aluminum capacity to serve beverage packaging, automotive and specialty product markets. The plant also includes a recycling center that will be capable of processing more than 15 billion used beverage cans annually.

All assets at Bay Minette required to commence commercial shipments are currently in the commissioning process. Novelis is working toward customer qualification and commercial shipments, which are on track to begin in the second quarter of 2027.

The highly advanced facility is expected to create up to 1,000 new jobs once fully operational.

About Novelis

Novelis Inc. is driven by its purpose of shaping a sustainable world together. We are a global leader in the production of innovative aluminum products and solutions and the world's largest recycler of aluminum. Our ambition is to be the leading provider of low-carbon, sustainable aluminum solutions and to achieve a fully circular economy by partnering with our suppliers, as well as our customers in the aerospace, automotive, beverage can and specialties industries throughout North America, Europe, Asia and South America. Novelis had net sales of $18.4 billion in fiscal year 2026. Novelis is a subsidiary of Hindalco Industries Limited, an industry leader in aluminum and copper, and the metals flagship company of the Aditya Birla Group, a multinational conglomerate based in Mumbai. For more information, visit novelis.com. 

Forward-Looking Statements

Statements made in this news release that describe Novelis' intentions, expectations, beliefs or predictions may be forward-looking statements within the meaning of securities laws. Forward-looking statements include statements preceded by, followed by, or including the words "believes," "expects," "anticipates," "plans," "estimates," "projects," "forecasts," or similar expressions. Examples of forward-looking statements in this news release include statements that: the Bay Minette investment will help meet long-term demand, the facility will add 600 kilotonnes of annual rolled aluminum capacity when fully operational, customer qualifications and commercial shipments are expected in the second quarter of 2027, and the facility is expected to create up to 1,000 new jobs. Novelis cautions that, by their nature, forward-looking statements involve risk and uncertainty. Novelis does not intend and disclaims any obligation, to update any forward-looking statements, whether as a result of new information, future events or otherwise. Important risk factors which could impact outcomes are included under the caption "Risk Factors" in Novelis' Form 10-K filed with the Securities and Exchange Commission for the fiscal year ended March 31, 2026, and as the same may be updated from time to time in Novelis' quarterly reports on Form 10-Q, or in other reports which we from time to time file with the SEC.

View original content to download multimedia:https://www.prnewswire.co.uk/news-releases/novelis-produces-first-coil-at-greenfield-aluminum-rolling-and-recycling-plant-in-alabama-302901242.html

Roche versucht nach einer Phase von Forschungsrückschlägen und Belastungen durch auslaufende Patente, das Tempo in der Medikamentenentwicklung deutlich zu erhöhen. Am Pharma-Investorentag unterstrich die Pharmasparte des Basler Konzerns den Anspruch, in Forschung und Entwicklung weiter zur Spitzengruppe zu gehören. Zentral sind dabei ein strengeres Management der Pipeline, Effizienzprogramme und der verstärkte Einsatz künstlicher Intelligenz entlang der Wertschöpfungskette.

Pharma-Chefin Teresa Graham verwies auf eine sichtbar verbesserte Bilanz seit dem letzten „Pharma Day“: In zehn zulassungsrelevanten Studien habe Roche die gesetzten Ziele erreicht, sechs Programme seien in die zulassungsrelevende Phase vorgerückt, drei weitere in Phase II. Insgesamt verfügt Roche nach eigenen Angaben über bis zu 20 neue Wirkstoffe, die bis 2030 auf den Markt kommen könnten. Einzelne Kandidaten wie das Brustkrebsmittel Giredestrant traut der Konzern dabei jeweils Spitzenumsätze im zweistelligen Milliardenbereich zu.

Um diese Ambitionen abzusichern, verschärft Roche die internen Selektionskriterien. Ende 2023 führte der Konzern mit „The Bar“ einen neuen Bewertungsrahmen für die Pipeline ein. Nur Wirkstoffkandidaten, die klar definierte Anforderungen erfüllen, werden weiterentwickelt. Medizinchef Levi Garraway bezeichnete „The Bar“ als Leitbild für Forschung und Entwicklung. Die Auswahl potenzieller Projekte sei damit spürbar strenger geworden – mit dem Ziel, Ressourcen konsequent auf die Erfolg versprechendsten Programme zu konzentrieren und die Erfolgsquote in späten Studienphasen zu stabilisieren oder weiter zu erhöhen.

Parallel dazu treibt Roche ein Effizienzprogramm voran, um Mittel aus weniger renditestarken in wachstumsstärkere Projekte umzuschichten. Die Entwicklung neuer Medikamente soll deutlich beschleunigt werden, was insbesondere in umkämpften Indikationen wie Onkologie sowie in wachstumsstarken Bereichen wie Herz-Kreislauf- und Stoffwechselerkrankungen an Bedeutung gewinnt. Damit will Roche erwartete Umsatzeinbussen durch Patentabläufe mehr als kompensieren und sich bis zum Ende des Jahrzehnts ein Portfolio aufbauen, das von mehreren potenziellen Blockbustern getragen wird.